Stock listing
BOATS:PALI Palisade Bio, Inc. Stock
US listing (BOATS) of Palisade Bio, Inc. · home listing NASDAQ:PALI
Follow Palisade Bio, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:PALI
$1.16 USD -0.03 (-2.5%)
Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PALI
- Day range
- $1.12 – $1.20 USDOct 30, 2026
- Volume
- 3.09M sharesOct 30, 2026
- Market cap
- $202.2M USDAt the close on Oct 30, 2026 · price × 174.3M shares outstanding
- 52-week range
- $1.10 – $2.86 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $4.46M USDMedian day 1.98M shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PALI · Home | $1.16 USD | -0.03 (-2.5%) | 3,090,528 | $1.18 | $1.20 | $1.12 | $1.19 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:PALI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.16 | -0.03 | -2.5% | $1.18 | $1.20 | $1.12 | 3,090,528 | |
| $1.19 | 0.00 | 0.0% | $1.20 | $1.25 | $1.15 | 3,499,620 | |
| $1.19 | -0.01 | -0.8% | $1.22 | $1.22 | $1.10 | 15,113,518 | |
| $1.20 | -0.03 | -2.4% | $1.22 | $1.255 | $1.17 | 6,011,066 | |
| $1.23 | -0.10 | -7.5% | $1.33 | $1.34 | $1.21 | 1,702,019 | |
| $1.33 | -0.02 | -1.5% | $1.35 | $1.37 | $1.28 | 1,153,900 | |
| $1.35 | -0.05 | -3.6% | $1.38 | $1.41 | $1.35 | 1,111,800 | |
| $1.40 | -0.03 | -2.1% | $1.44 | $1.46 | $1.39 | 1,432,800 | |
| $1.43 | +0.09 | +6.7% | $1.39 | $1.48 | $1.34 | 2,817,400 | |
| $1.34 | -0.07 | -5.0% | $1.41 | $1.46 | $1.32 | 1,834,400 | |
| $1.41 | -0.13 | -8.4% | $1.55 | $1.56 | $1.40 | 3,888,900 | |
| $1.54 | +0.06 | +4.1% | $1.50 | $1.56 | $1.48 | 1,817,600 | |
| $1.48 | +0.01 | +0.7% | $1.45 | $1.51 | $1.38 | 4,162,500 | |
| $1.47 | -0.12 | -7.5% | $1.56 | $1.58 | $1.46 | 1,587,900 | |
| $1.59 | +0.05 | +3.2% | $1.53 | $1.63 | $1.51 | 1,571,700 | |
| $1.54 | +0.09 | +6.2% | $1.49 | $1.57 | $1.47 | 1,840,400 | |
| $1.45 | -0.03 | -2.0% | $1.47 | $1.48 | $1.38 | 2,083,900 | |
| $1.48 | -0.01 | -0.7% | $1.46 | $1.48 | $1.44 | 825,200 | |
| $1.49 | +0.03 | +2.1% | $1.51 | $1.55 | $1.47 | 1,972,700 | |
| $1.46 | +0.02 | +1.4% | $1.44 | $1.48 | $1.41 | 1,595,700 | |
| $1.44 | +0.01 | +0.7% | $1.46 | $1.48 | $1.43 | 1,993,500 | |
| $1.43 | +0.08 | +5.9% | $1.39 | $1.46 | $1.37 | 2,644,700 | |
| $1.35 | -0.10 | -6.9% | $1.44 | $1.46 | $1.32 | 4,765,200 | |
| $1.45 | -0.05 | -3.3% | $1.54 | $1.55 | $1.42 | 2,164,000 | |
| $1.50 | +0.05 | +3.4% | $1.45 | $1.53 | $1.43 | 8,683,300 | |
| $1.45 | -0.12 | -7.6% | $1.57 | $1.59 | $1.45 | 5,780,700 | |
| $1.57 | -0.03 | -1.9% | $1.60 | $1.60 | $1.50 | 3,257,200 | |
| $1.60 | -0.09 | -5.3% | $1.69 | $1.70 | $1.59 | 2,941,400 | |
| $1.69 | 0.00 | 0.0% | $1.71 | $1.71 | $1.60 | 4,982,600 | |
| $1.69 | +0.10 | +6.3% | $1.64 | $1.69 | $1.60 | 3,574,200 | |
| $1.59 | -0.11 | -6.5% | $1.68 | $1.72 | $1.59 | 6,869,400 | |
| $1.70 | +0.01 | +0.6% | $1.75 | $1.76 | $1.65 | 5,396,600 | |
| $1.69 | -0.33 | -16.3% | $2.04 | $2.04 | $1.67 | 8,407,600 | |
| $2.02 | -0.03 | -1.5% | $2.05 | $2.06 | $1.96 | 4,489,400 | |
| $2.05 | -0.01 | -0.5% | $2.05 | $2.11 | $2.02 | 1,813,500 | |
| $2.06 | +0.05 | +2.5% | $2.05 | $2.10 | $2.02 | 2,399,400 | |
| $2.01 | -0.04 | -2.0% | $2.05 | $2.11 | $2.01 | 2,646,400 | |
| $2.05 | -0.15 | -6.8% | $2.17 | $2.21 | $2.05 | 2,774,700 | |
| $2.20 | +0.11 | +5.3% | $2.09 | $2.24 | $2.08 | 3,529,800 | |
| $2.09 | +0.04 | +2.0% | $2.03 | $2.12 | $2.00 | 1,755,300 | |
| $2.05 | +0.06 | +3.0% | $2.01 | $2.05 | $1.97 | 1,086,600 | |
| $1.99 | +0.03 | +1.5% | $1.96 | $2.01 | $1.95 | 730,700 | |
| $1.96 | +0.01 | +0.5% | $1.96 | $1.98 | $1.92 | 879,400 | |
| $1.95 | -0.05 | -2.5% | $2.02 | $2.02 | $1.93 | 1,645,100 | |
| $2.00 | -0.11 | -5.2% | $2.10 | $2.11 | $1.99 | 2,127,100 | |
| $2.11 | -0.02 | -0.9% | $2.12 | $2.16 | $2.10 | 899,100 | |
| $2.13 | +0.06 | +2.9% | $2.06 | $2.14 | $2.03 | 1,190,100 | |
| $2.07 | +0.06 | +3.0% | $2.02 | $2.10 | $1.98 | 2,068,108 | |
| $2.01 | -0.09 | -4.3% | $2.10 | $2.10 | $2.00 | 1,618,511 | |
| $2.10 | +0.04 | +1.9% | $2.09 | $2.14 | $2.08 | 1,070,300 | |
| $2.06 | -0.10 | -4.6% | $2.14 | $2.15 | $2.03 | 1,324,900 | |
| $2.16 | +0.12 | +5.9% | $2.10 | $2.19 | $2.09 | 2,290,000 | |
| $2.04 | -0.11 | -5.1% | $2.15 | $2.15 | $2.01 | 2,286,300 | |
| $2.15 | +0.01 | +0.5% | $2.13 | $2.22 | $2.10 | 1,404,000 | |
| $2.14 | -0.01 | -0.5% | $2.12 | $2.15 | $2.06 | 1,605,500 | |
| $2.15 | +0.19 | +9.7% | $1.99 | $2.15 | $1.98 | 2,466,600 | |
| $1.96 | -0.18 | -8.4% | $2.14 | $2.18 | $1.95 | 2,376,600 | |
| $2.14 | +0.04 | +1.9% | $2.05 | $2.15 | $2.05 | 1,245,700 | |
| $2.10 | -0.01 | -0.5% | $2.05 | $2.10 | $2.03 | 1,308,900 | |
| $2.11 | +0.02 | +1.0% | $2.08 | $2.12 | $2.05 | 886,500 | |
| $2.09 | -0.03 | -1.4% | $2.09 | $2.15 | $2.07 | 779,200 | |
| $2.12 | +0.05 | +2.4% | $2.05 | $2.14 | $2.05 | 1,979,700 | |
| $2.07 | +0.13 | +6.7% | $1.93 | $2.08 | $1.92 | 1,646,400 | |
| $1.94 | +0.04 | +2.1% | $1.90 | $1.97 | $1.89 | 1,027,200 | |
| $1.90 | -0.06 | -3.1% | $1.94 | $1.95 | $1.86 | 1,853,400 | |
| $1.96 | 0.00 | 0.0% | $1.95 | $1.99 | $1.94 | 1,010,700 |
- Ticker
- BOATS:PALI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
Oct 28, 2026
Closed $1.19 (-0.8%) on Oct 28, 2026
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Oct 20, 2026
Closed $1.43 (+6.7%) on Oct 20, 2026
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
Oct 12, 2026
Closed $1.59 (+3.2%) on Oct 12, 2026
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Sep 28, 2026
Closed $1.50 (+3.4%) on Sep 28, 2026
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Sep 23, 2026
Closed $1.60 (-5.3%) on Sep 23, 2026
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
Sep 22, 2026
Closed $1.69 (0.0%) on Sep 22, 2026
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Sep 21, 2026
Closed $1.69 (+6.3%) on Sep 21, 2026
Palisade Bio to Participate in Upcoming Investor Conferences
Sep 3, 2026
Closed $2.05 (+3.0%) on Sep 3, 2026
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Aug 10, 2026
Closed $2.14 (+1.9%) on Aug 11, 2026
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Jul 10, 2026
Closed $1.96 (-0.5%) on Jul 10, 2026
Decks
STAR Annual Meeting 2025
Conference · 18 slides · September 2025
8th Anti-Fibrotic Drug Development Summit (November 2024)
Conference · 17 slides · November 2024
IBD Innovate 2024
Conference · 27 slides · April 2024
Investor Presentation (November 2023)
Investor deck · 26 slides · Nov 7, 2023
Palisade Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 159 in all · newest Oct 28, 2026 · oldest 2021
- Decks
- 42 decks · latest September 2025
Where Palisade Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PALI · Home listing | NASDAQ | United States | USD |
| BOATS:PALI · This page | BOATS | United States | USD |
| gettex:7NS0 | gettex | Germany | EUR |
| Frankfurt:7NS0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A4098S | Lang & Schwarz | Germany | EUR |
| Munich:7NS0 | Munich | Germany | EUR |
Log in to ask 6ix AI your own questions about Palisade Bio, Inc.